These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 32562206)

  • 1. Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial.
    Nicolau JC; Bhatt DL; Hohnloser SH; Kimura T; Lip GYH; Miede C; Nordaby M; Oldgren J; Steg PG; Ten Berg JM; Godoy LC; Cannon CP;
    Drugs; 2020 Jul; 80(10):995-1005. PubMed ID: 32562206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial.
    Berry NC; Mauri L; Steg PG; Bhatt DL; Hohnloser SH; Nordaby M; Miede C; Kimura T; Lip GYH; Oldgren J; Ten Berg JM; Cannon CP
    Circ Cardiovasc Interv; 2020 Apr; 13(4):e008349. PubMed ID: 32252548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the RE-DUAL PCI Trial).
    Ten Berg JM; Steg PG; Bhatt DL; Hohnloser SH; de Veer A; Nordaby M; Miede C; Kimura T; Lip GYH; Oldgren J; Cannon CP;
    Am J Cardiol; 2020 Mar; 125(5):735-743. PubMed ID: 31924322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes.
    Maeng M; Steg PG; Bhatt DL; Hohnloser SH; Nordaby M; Miede C; Kimura T; Lip GYH; Oldgren J; Ten Berg JM; Cannon CP;
    JACC Cardiovasc Interv; 2019 Dec; 12(23):2346-2355. PubMed ID: 31806216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis.
    Ten Berg JM; de Veer A; Oldgren J; Steg PG; Zateyshchikov DA; Jansky P; Seung KB; Hohnloser SH; Lip GYH; Nordaby M; Kleine E; Bhatt DL; Cannon CP;
    JACC Cardiovasc Interv; 2019 Dec; 12(23):2331-2341. PubMed ID: 31806214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.
    Oldgren J; Steg PG; Hohnloser SH; Lip GYH; Kimura T; Nordaby M; Brueckmann M; Kleine E; Ten Berg JM; Bhatt DL; Cannon CP
    Eur Heart J; 2019 May; 40(19):1553-1562. PubMed ID: 30793734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
    Cannon CP; Bhatt DL; Oldgren J; Lip GYH; Ellis SG; Kimura T; Maeng M; Merkely B; Zeymer U; Gropper S; Nordaby M; Kleine E; Harper R; Manassie J; Januzzi JL; Ten Berg JM; Steg PG; Hohnloser SH;
    N Engl J Med; 2017 Oct; 377(16):1513-1524. PubMed ID: 28844193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial.
    Lip GYH; Mauri L; Montalescot G; Ozkor M; Vardas P; Steg PG; Bhatt DL; Hohnloser SH; Miede C; Nordaby M; Brueckmann M; Kreuzer J; Kimura T; Oldgren J; Ten Berg JM; Cannon CP
    Am Heart J; 2019 Jun; 212():13-22. PubMed ID: 30928824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI.
    Hohnloser SH; Steg PG; Oldgren J; Nickenig G; Kiss RG; Ongen Z; Navarro Estrada JL; Oude Ophuis T; Lip GYH; Nordaby M; Kleine E; Ten Berg JM; Bhatt DL; Cannon CP;
    JACC Cardiovasc Interv; 2019 Aug; 12(16):1553-1561. PubMed ID: 31439336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after PCI in patients with atrial fibrillation (a RE-DUAL PCI subgroup analysis and comparison to other dual antithrombotic therapy trials).
    Eccleston DS; Kim JM; Ten Berg JM; Steg PG; Bhatt DL; Hohnloser SH; de Veer A; Nordaby M; Miede C; Kimura T; Lip GYH; Oldgren J; Cannon CP
    Clin Cardiol; 2021 Jul; 44(7):1002-1010. PubMed ID: 34042199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Dabigatran Plus a P2Y
    De Caterina R; Procopio A; Lopez Sendon JL; Raev D; Mehta SR; Opolski G; Oldgren J; Steg PG; Hohnloser SH; Lip GYH; Kimura T; Kleine E; Ten Berg JM; Bhatt DL; Miede C; Nordaby M; Cannon CP;
    Am J Med; 2020 Nov; 133(11):1302-1312. PubMed ID: 32389658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting.
    Cannon CP; Gropper S; Bhatt DL; Ellis SG; Kimura T; Lip GY; Steg PG; Ten Berg JM; Manassie J; Kreuzer J; Blatchford J; Massaro JM; Brueckmann M; Ferreiros Ripoll E; Oldgren J; Hohnloser SH;
    Clin Cardiol; 2016 Oct; 39(10):555-564. PubMed ID: 27565018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST-segment elevation myocardial infarction: a post hoc analysis of the randomised RE-DUAL PCI trial.
    Zeymer U; Leiva O; Hohnloser SH; Steg PG; Oldgren J; Nickenig G; Gabor Kiss R; Ongen Z; Navarro Estrada J; Oude Ophuis T; Lip GYH; Nordaby M; Miede C; Ten Berg JM; Bhatt DL; Cannon CP
    EuroIntervention; 2021 Aug; 17(6):474-480. PubMed ID: 33164896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual Anti-Thrombotic Therapy With Dabigatran After Percutaneous Coronary Intervention in Atrial Fibrillation　- Japanese and East-Asian Subgroup Analysis of the RE-DUAL PCI Trial.
    Ako J; Okumura K; Nakao K; Kozuma K; Morino Y; Okazaki K; Fukaya T; Kimura T;
    Circ J; 2019 Jan; 83(2):327-333. PubMed ID: 30643079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial.
    Peterson BE; Bhatt DL; Gabriel Steg P; Oldgren J; Maeng M; Zeymer U; Halvorsen S; Hohnloser SH; Lip GYH; Kimura T; Nordaby M; Miede C; Kleine E; Ten Berg JM; Cannon CP;
    JACC Cardiovasc Interv; 2021 Apr; 14(7):768-780. PubMed ID: 33826497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI.
    Costa F; Valgimigli M; Steg PG; Bhatt DL; Hohnloser SH; Ten Berg JM; Miede C; Nordaby M; Lip GYH; Oldgren J; Cannon CP
    Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):216-226. PubMed ID: 33258897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in Antiplatelet and Anticoagulant Therapies for NSTE-ACS.
    Badjatiya A; Rao SV
    Curr Cardiol Rep; 2019 Jan; 21(1):3. PubMed ID: 30637536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of rivaroxaban and ticagrelor in elderly patients with atrial fibrillation undergoing percutaneous coronary intervention.
    Liu X; Wang L; Zhou M; Feng L
    Contemp Clin Trials; 2021 May; 104():106365. PubMed ID: 33746024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention.
    Chi G; Yee MK; Kalayci A; Kerneis M; AlKhalfan F; Mehran R; Bode C; Halperin JL; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Peterson ED; Fox KAA; Gibson CM
    J Thromb Thrombolysis; 2018 Oct; 46(3):346-350. PubMed ID: 29943350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?
    Duerschmied D; Brachmann J; Darius H; Frey N; Katus HA; Rottbauer W; Schäfer A; Thiele H; Bode C; Zeymer U
    Clin Res Cardiol; 2018 Jul; 107(7):533-538. PubMed ID: 29679144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.